Physicians' Academy for Cardiovascular Education

First T2DM medicine in EU to receive expansion of indication to lower CV death

Feb. 13, 2017 - news

Based on EMPA-REG OUTCOME data, the European Commission has for the first time approved an agent against type 2 diabetes, empagliflozin, to both lower blood glucose and the risk of CV events.

Large NOAC trial stopped early as primary endpoint was reached ahead of time

Feb. 9, 2017 - news
Rivaroxaban significantly reduced CV events in patients with coronary or peripheral disease in COMPASS trial

Rivaroxaban significantly reduced CV events in patients with coronary or peripheral disease in COMPASS trial

Few adverse events of very low LDL-C levels with PCSK9 antibody

Feb. 8, 2017 - Robinson JG, et al. - J Am Coll Cardiol. 2017

In a meta-analysis with more than 5 000 patients with a median alirocumab exposure of 1.5 years, low levels of LDL-C (<25 mg/dl) were associated with an increased incidence of cataracts.

Midlife cholesterol levels predict Alzheimer disease with ASCVD

Feb. 8, 2017 - Rantanen K, et al. - Ann Med. 2017

After 49 years follow-up, the HBS study found that high cholesterol levels predict Alzheimer disease with atherosclerotic vascular disease (ASCVD), but not without ASCVD or with vascular dementia.

Timing and frequency of meals important for cardiovascular disease prevention

Feb. 7, 2017 - news

Irregular eating patterns appear less favourable for maintaining body weight and optimal cardiometabolic health.

PCSK9 inhibitor increases the removal of LDL and Lp(a) from the circulation via LDL-receptors

Feb. 7, 2017 - Reyes-Soffer G et al. - Circulation. 2017

Alirocumab treatment of healthy volunteers reduced LDL-C and LDL-apoB concentrations and doubled the efficiency with which LDL particles were removed from the circulation.

PCSK9 inhibitor non-inferior to placebo for effect on cognitive function

Feb. 3, 2017 - news
Evolocumab FOURIER CV outcomes study lowers CV risk in high-risk patients. Simultaneously, a trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

The evolocumab EBBINGHAUS trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

PCSK9 inhibitor significantly reduced CV risk in ASCVD patients in FOURIER outcomes study

Feb. 3, 2017 - news
Evolocumab FOURIER CV outcomes study lowers CV risk in high-risk patients. Simultaneously, a trial showed that the antibody against PCSK9 is non-inferior to placebo for the effect on cognitive function.

Evolocumab CV outcomes study meets primary and key secondary endpoints, showing reduced risk of CV events in those with ASCVD already on optimised statin therapy.

10% sodium intake reduction over 10 years cost effective in all nations

Feb. 2, 2017 - Webb M, et al. - BMJ, 2017

10% sodium intake reduction over 10 years achieved by education, government and industry regulations was estimated to be most cost effective in all and extremely cost effective in nearly all of 183 nations evaluated.

Depression and exhaustion predict CVD mortality

Feb. 2, 2017 - Ladwig KH, et al. - Atherosclerosis 2017

Depression and exhaustion predict lower life expectancy and higher CVD mortality risk with an effect size comparable to traditional major risk factors.

No association non-fasting triglycerides with subclinical atherosclerosis

Feb. 1, 2017 - Christen T, et al. - J Clin Lipidol, 2017

Although crude triglyceride response after a meal was associated with difference in carotid intima media thickness, this association was lost after correction for age, sex and fasting triglycerides.

Non-HDL-C a better predictor of mortality than LDL-C

Feb. 1, 2017 - Harari G, et al. - Am J Cardiol 2017

In a large population of young males who were followed-up for 22 years, non-HDL-C was a more potent predictor of CVD mortality than LDL-C.

3' education

Get involved in May Measurement Month!

Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President

Tailoring oral anticoagulation in elderly patients with AF

Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)

How low to go with blood pressure: J-curve or not?

Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)

Shifting priorities of care for older cardiac patients

Nov. 12, 2016 - New Orleans, LA, USA - Daniel E. Forman, MD (Pittsburgh, PA, USA)

HFpEF in older adults: TTR amyloid, under diagnosed and treatable?

Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)

Advancing CV care of cancer patients: Where are we now?

Nov. 12, 2016 - New Orleans, LA, USA - Javid J. Moslehi, MD (Nashville, TN, USA)

Modifying CV risk by managing diabetes

Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)

Blood pressure control in CKD in older people

Nov. 12, 2016 - New Orleans, LA, USA - Prof. George L Bakris, MD (Chicago, IL, USA)

Emerging therapies and treatment strategies in pulmonary arterial hypertension

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul R. Forfia, MD - Philadelphia, PA, USA

Promising results in pivotal trials of novel lipid-modifying drugs

Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)

Investigational epigenetic therapy lowers incidence of MACE in phase 2b study

Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada

No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease

Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands

CAC reveals evidence of coronary artery calcification in third of low-risk women

Nov. 14, 2016 - AHA, New Orleans, LA, USA - Dr. Maryam Kavousi, Rotterdam, The Netherlands

Outstanding questions and ongoing studies on the use of NOACs

Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)

Lipid-lowering in the elderly - considering net benefit

Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Peak VO2 maintained in HF patients on IV iron therapy

Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study

Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Brief update on various pharmacotherapeutic strategies to lower CV risk

Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression

Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Iron deficiency in the new HF guidelines

Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Extra work of checking device data weekly does not translate into benefit for HF patient

Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Customising therapy approach in ACS based on underlying pathology seems promising

Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

No added value of monitoring platelet function after ACS

Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany

No indication for difference in efficacy between potent platelet inhibitors after PCI

Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life

Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Mendelian randomisation study suggests that CV prevention could be simpler and more effective

Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Heart Failure news from ESC 2016 at a glance

Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A changing treatment paradigm in diabetes

July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibition in diabetic kidney disease

Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)

New agents to treat hyperkalaemia

July 18, 2016 - ACC 2016 - Bertram Pitt, MD

Exciting times in diabetes treatment: new drug class moves beyond glucose reduction

Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Novel small molecule that inhibits PAI-1 in development to slow vascular aging

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA

Two additions to the therapeutic armory to treat HFrEF

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA

Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA

How to treat residual inflammatory risk?

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA

Evolving hypotheses on the mechanisms underlying ACS

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA

New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA

Elucidating the role of gut microbes in CVD may provide future therapeutic strategies

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA

Steps forward in lipid-lowering therapy

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA

Managing cardiorenal syndrome in the context of heart failure

Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA

HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations

May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Statin lowers CV risk, in absence of LDL-c measurement

Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

New 2016 ESC Heart Failure Guidelines

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM

May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
##RIGHT_SECTION_ITEMS_FULL_TITLE##

CV protection by SGLT2 inhibition: Potential mechanisms for benefit

May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands

Review of cardiovascular safety of DPP4 inhibitors

May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Stroke reduction with PPAR-Y antagonist pioglitazone

May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
##RIGHT_SECTION_ITEMS_FULL_TITLE##

No benefit of direct renin inhibition in HF in ATMOSPHERE trial

Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
##RIGHT_SECTION_ITEMS_FULL_TITLE##

10' education

Careful implementation of PCSK9 inhibitors in clinical practice

Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)

A minority of FH patients is identified and labeled as such, which impacts treatment

Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Possible approaches in precision medicine for secundary CV prevention

Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)

Would lower than the current ApoB targets be more useful for clinical decision-making?

Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).

Bisphosphonate as a potential new treatment for CV risk reduction

Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)

Oral anticoagulation in daily clinical practice in varous patient populations

Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)

Understanding why patients do not take their medication and stimulating adherence

Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)

What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?

Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)

Interim results of new device for treatment resistant hypertension

Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)

Targeting residual inflammatory risk as a strategy to lower CV risk

Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)

Heart failure news at the ESC

Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
##RIGHT_SECTION_ITEMS_FULL_TITLE##

To SPRINT or not to SPRINT to a lower blood pressure target?

Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)

Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies

Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome

Beyond statins: The role of ezetimibe in targeting residual risk

Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom

Inflammation as potential target for therapy to target residual risk post ACS

Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?

Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

PCSK9, the short track road from discovery as drug target towards the clinic

Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France

Surviving elevated Lp(a): a patient story from diagnosis to treatment

May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

A patient with elevated Lp(a): What is current clinical practice to manage this condition?

May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

The future perspectives for care for patients with high Lp(a)

May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS

HF & Diabetes: SGLT2 inhibition a paradigm shift?

Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome

Challenging cardiovascular risk in diabetes: ready for a new approach?

Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom

Overview of SGLT-2 inhibitors in T2DM management: current position & future promise

Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

BET inhibition in cardiovascular disease: A new dawn?

Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016

The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?

Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?

June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway

Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit

May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK

Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure

May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands

RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis

May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France

SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials

May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada

Current treatment of Diabetes in Heart Failure

May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands

BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk

May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

The spectrum of Heart Failure

May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
##RIGHT_SECTION_ITEMS_FULL_TITLE##

What surprises have emerged from genetic studies of coronary artery disease?

Apr. 25, 2016 - Boston, MA, USA - Dr. Sekar Kathiresan (Boston, MA, USA)
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diabetic dyslipidaemia and residual risk in the era of LDL control

Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
##RIGHT_SECTION_ITEMS_FULL_TITLE##

How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?

Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Changing views on mechanisms of atherosclerosis

Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)

HF Summit : innovation in clinical care in heart failure

Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
##RIGHT_SECTION_ITEMS_FULL_TITLE##

A multidisciplinary approach in heart failure management

Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibitor outcome trials: Future opportunities

Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
##RIGHT_SECTION_ITEMS_FULL_TITLE##

SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk

Sep. 29, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

What is the story about Diabetes & CVD: Rationale for a multifactorial approach

Sep. 29, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Diabetes & Cardiovascular Disease:The risk factor to be challenged

Sep. 27, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

Sep. 24, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation as target for therapy in atherothrombosis

Aug. 31, 2015 - ESC London - Prof Paul M Ridker
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation and Thrombosis

Sep. 29, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##

Inflammation in Acute Myocardial Infarction & Ventricular Remodelling

Oct. 21, 2015 - ESC 2015, London UK at Monday, August 31, 2015
##RIGHT_SECTION_ITEMS_FULL_TITLE##